MedicineEurope PMC
Heuristic editor, no API keyVerdict: MajorOral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial
Background Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation.
Key numbers
- 95% CI
VerdictA leading story on any desk.
Abstract
Background Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation. Mutations in TET2 are common drivers of leukemia. Preclinical studies suggest that VitC may delay leukemia progression. This study aimed to evaluate the biological activity, safety, and clinical impact of oral VitC in patients with clonal cytopenia of undetermined significance (CCUS) or lower risk myeloid malignancies. Methods EVITA (Epigenetics, Vitamin C, and Abnormal Hematopoiesis) was a double-blind, randomized, placebo-controlled, phase 2 trial conducted in Denmark and the United States. Adults with CCUS or lower risk myeloid malignancies not receiving anticancer therapy were randomly assigned (1:1) to receive oral VitC (1000 mg/day) or placebo for 12 months, followed by long-term follow-up. The primary end point was the median clonal growth rate from baseline to end of treatment. EVITA was registered at ClinicalTrials.gov (NCT03682029), and is now completed. Results Between November 1, 2017, and September 28, 2022, 109 patients were enrolled (VitC, n = 55; placebo, n = 54). Although the primary end point, median clonal growth rate, did not differ between groups (-0.016; 95% CI, -0.096 to 0.064; p = .70), secondary outcomes included differences in inflammatory cytokine trajectories and fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]). In exploratory analyses, overall survival was significantly longer with VitC (hazard ratio, 0.35; 95% CI, 0.17 to 0.71; p = .0025). Conclusions These findings suggest oral VitC as a safe, biologically active intervention in patients with early-stage myeloid malignancies and precursor conditions. A phase 3 trial is warranted.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 10% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ███░░ 3 | 20% | Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem. |
| Evidence | █████ 5 | 32% | Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale. |
| Novelty | ██░░░ 2 | 8% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 5% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (efficacy); design (randomized, blinded, placebo-controlled); verification (confidence interval, p-value); stakes (mortality, major disease, prevention or cure). Red flags: weak evidence (preliminary).
How the score was computed
- Merit
- 6.8 / 10
- Adjusted merit
- 5.4 / 10
- Attention
- 0%
- Freshness
- 98%
- Citations0 (reference 20, via openalex, Oct 1, 2026, 06:17 UTC)
- Field-weighted citation impact0 (reference 3, via openalex, Oct 1, 2026, 06:17 UTC)